Predication of Response to Disease Modifying Therapy in Multiple Sclerosis.

Abstract

MS is an idiopathic inflammatory disease of the CNS and the second most common cause of disability in young adults. Choosing an effective treatment is crucial to preventing disability. However, response to treatment varies greatly between patients. Because of this, accurate and timely detection of individual response to treatment is an essential requisite of efficient personalized MS therapy (Preunza et al., 2019) In this retrospective study 150 patients with confirmed diagnosis of RRMS was recruited from the MS unit at the Neurology departments from both Ain Shams University and Cairo University Students hospital. All of the study population were receiving either interferons or fingolimod . The study aimed was to identify predictors of DMT after one year of treatment. Modified rio score was used to classify patient to responders and non responders. In this study 128 patient were found responders and 22 were found non responders. There was a significant difference between responders and non-responders regarding age of the participants. that the age was significantly older in responders compared to non-responders (mean of 32.37±7.248 versus 28.55±5.361 years respectively; P = 0.019).